Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| GEND_GBV |
By PEP service provision (related to sexual violence services provided) |
2017 |
54 |
| GEND_GBV |
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) |
2017 |
40 |
| GEND_GBV |
By type of service: Sexual Violence (Post-Rape Care) |
2017 |
60 |
| GEND_GBV |
Number of people receiving post-GBV care |
2017 |
100 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2017 |
3,000 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2017 |
3,000 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2017 |
12,000 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2017 |
42,000 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2017 |
60,000 |
| HTS_TST |
Service Delivery Point (Facility): Index testing |
2017 |
3,000 |
| HTS_TST |
Service Delivery Point (Facility): Inpatient |
2017 |
3,000 |
| HTS_TST |
Service Delivery Point (Facility): Other PITC |
2017 |
22,657 |
| HTS_TST |
Service Delivery Point (Facility): Outpatient |
2017 |
6,000 |
| HTS_TST |
Service Delivery Point (Facility): Pediatric |
2017 |
6,000 |
| HTS_TST |
Service Delivery Point (Facility): PMTCT |
2017 |
2,543 |
| HTS_TST |
Service Delivery Point (Facility): TB Clinics |
2017 |
1,800 |
| HTS_TST |
Service Delivery Point (Facility): VCT |
2017 |
15,000 |
| HTS_TST |
Sum of Aggregated Age/Sex <15 |
2017 |
6,000 |
| HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2017 |
54,000 |
| HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2017 |
60,000 |
| LAB_PT |
CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2017 |
11 |
| LAB_PT |
CD4: Number of laboratories that participate in this PT program |
2017 |
11 |
| LAB_PT |
CD4: Number of laboratories that perform this testing |
2017 |
11 |
| LAB_PT |
Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2017 |
1 |
| LAB_PT |
Early infant diagnostics: Number of laboratories that participate in this PT program |
2017 |
1 |
| LAB_PT |
Early infant diagnostics: Number of laboratories that perform this testing |
2017 |
1 |
| LAB_PT |
HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2017 |
67 |
| LAB_PT |
HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program |
2017 |
67 |
| LAB_PT |
HIV serologic/diagnostic testing: Number of laboratories that perform this testing |
2017 |
67 |
| LAB_PT |
HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2017 |
1 |
| LAB_PT |
HIV viral load: Number of laboratories that participate in this PT program |
2017 |
1 |
| LAB_PT |
HIV viral load: Number of laboratories that perform this testing |
2017 |
1 |
| LAB_PT |
TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2017 |
33 |
| LAB_PT |
TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program |
2017 |
33 |
| LAB_PT |
TB diagnostics (AFB microscopy): Number of laboratories that perform this testing |
2017 |
33 |
| LAB_PT |
TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2017 |
1 |
| LAB_PT |
TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program |
2017 |
1 |
| LAB_PT |
TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing |
2017 |
1 |
| PMTCT_ART |
Already on ART at beginning of current pregnancy |
2017 |
45 |
| PMTCT_ART |
New on ART |
2017 |
27 |
| PMTCT_ART |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2017 |
2,590 |
| PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2017 |
55 |
| PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2017 |
13 |
| PMTCT_EID |
Sum of Infant Age disaggregates |
2017 |
68 |
| PMTCT_STAT |
By: Known positives at entry |
2017 |
47 |
| PMTCT_STAT |
By: Number of new positives identified |
2017 |
28 |
| PMTCT_STAT |
Number of new ANC and L&D clients |
2017 |
2,726 |
| PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2017 |
2,590 |
| PMTCT_STAT |
Sum of Positives Status disaggregates |
2017 |
75 |
| PP_PREV |
Aggregated Age/sex: 15+ Female |
2017 |
9,500 |
| PP_PREV |
Aggregated Age/sex: 15+ Male |
2017 |
67,000 |
| PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2017 |
76,500 |
| TB_ART |
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2017 |
12 |
| TB_ART |
Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2017 |
48 |
| TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period |
2017 |
60 |
| TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2017 |
60 |
| TB_SCREENDX |
[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB |
2017 |
4,012 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) |
2017 |
1,720 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only |
2017 |
1,204 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay |
2017 |
1,605 |
| TB_SCREENDX |
Screen Result: Screened Positive for TB |
2017 |
576 |
| TB_SCREENDX |
Screened for TB by Age/Sex: 15+ Female |
2017 |
1,996 |
| TB_SCREENDX |
Screened for TB by Age/Sex: 15+ Male |
2017 |
3,480 |
| TB_SCREENDX |
Screened for TB by Age/Sex:<15 Female |
2017 |
115 |
| TB_SCREENDX |
Screened for TB by Age/Sex:<15 Male |
2017 |
141 |
| TB_SCREENDX |
The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period |
2017 |
5,732 |
| TB_STAT |
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2017 |
5 |
| TB_STAT |
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2017 |
36 |
| TB_STAT |
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2017 |
5 |
| TB_STAT |
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2017 |
140 |
| TB_STAT |
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period |
2017 |
186 |
| TB_STAT |
Total number of registered new and relapsed TB cases, during the reporting period |
2017 |
190 |
| TX_CURR |
Aggregated Age/Sex: <15 Female |
2017 |
128 |
| TX_CURR |
Aggregated Age/Sex: <15 Male |
2017 |
157 |
| TX_CURR |
Aggregated Age/Sex: 15+ Female |
2017 |
2,218 |
| TX_CURR |
Aggregated Age/Sex: 15+ Male |
2017 |
3,866 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2017 |
6,369 |
| TX_CURR |
Sum of Aggregated Age/Sex <15 |
2017 |
285 |
| TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2017 |
6,084 |
| TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2017 |
6,369 |
| TX_NEW |
Aggregated Grouping by Age/Sex: <15 Female |
2017 |
17 |
| TX_NEW |
Aggregated Grouping by Age/Sex: <15 Male |
2017 |
17 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2017 |
203 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2017 |
351 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2017 |
588 |
| TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2017 |
588 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2017 |
3,822 |
| TX_PVLS |
Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months |
2017 |
3,439 |
| TX_PVLS |
Numerator Aggregated Age/Sex: <15 Female |
2017 |
69 |
| TX_PVLS |
Numerator Aggregated Age/Sex: <15 Male |
2017 |
85 |
| TX_PVLS |
Numerator Aggregated Age/Sex: 15+ Female |
2017 |
1,197 |
| TX_PVLS |
Numerator Aggregated Age/Sex: 15+ Male |
2017 |
2,088 |
| TX_PVLS |
Numerator: Indication: Routine |
2017 |
3,439 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: <15 Female |
2017 |
77 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: <15 Male |
2017 |
94 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: 15+ Female |
2017 |
1,331 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: 15+ Male |
2017 |
2,320 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2017 |
3,821 |
| TX_RET |
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
8 |
| TX_RET |
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
12 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
129 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
268 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2017 |
417 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2017 |
490 |
| TX_RET_den |
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
14 |
| TX_RET_den |
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
13 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
148 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
315 |
